MedTrace Logo

Acute Effects of Patellar Tendon Ultrasound on Countermovement Jump Performance

NCT07507695 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2026-04-02

No results posted yet for this study

Summary

This randomized, double-blind, controlled trial aims to investigate the acute effects of therapeutic ultrasound applied to the patellar tendon on vertical jump performance in healthy university students. Therapeutic ultrasound is widely used in physiotherapy to influence soft tissue properties through thermal and mechanical effects; however, its immediate impact on explosive lower-extremity performance and neuromuscular function remains unclear.

Participants will be randomly assigned to either a therapeutic ultrasound group or a sham ultrasound (placebo) group. In the intervention group, therapeutic ultrasound will be applied to the patellar tendon using a frequency of 1 MHz and an intensity of 1.5 W/cm² in continuous mode for 5 minutes. In the control group, a sham ultrasound procedure will be performed using the same device and duration without delivering therapeutic energy. Both the participants and the outcome assessor will be blinded to group allocation.

Vertical jump performance will be evaluated using the countermovement jump (CMJ) test recorded with the My Jump 2 smartphone application. In addition, quadriceps muscle strength will be measured using a hand-held dynamometer, and knee joint position sense will be assessed using a joint position reproduction test. All measurements will be conducted before and immediately after the intervention.

This study will provide evidence regarding whether therapeutic ultrasound applied to the patellar tendon can acutely influence explosive performance, muscle strength, and proprioception in healthy individuals.

Conditions

  • Muscle Performance

Interventions

OTHER

therapeutic ultrasound Group

The use of therapeutic ultrasound on the patellar tendon in healthy individuals.

Sponsors & Collaborators

  • Muş Alparslan University

    lead OTHER

Principal Investigators

  • Cengiz TAŞKAYA · Muş Alparslan University

  • Burhan TAŞKAYA · Muş Alparslan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-04-20
Primary Completion
2026-04-27
Completion
2026-05-01

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07507695 on ClinicalTrials.gov